Abstract. Single iv doses (25, 50 and 100 \ g=m\ g) of medetomidine, a selective \g=a\2-adrenoceptor agonist of the imidazole type, were administered to 8 healthy male volunteers in a randomized, double-blind, placebocontrolled study. The concentration of hGH in plasma was powerfully and dose-dependently increased. The plasma level of cortisol was dose-dependently decreased, whereas TSH showed a slight but statistically significant increase. Plasma levels of PRL, FSH and LH were unaffected by the drug. Medetomidine appears to resemble other \g=a\2-adrenoceptor agonists, notably clonidine, in its endocrine effects. Its high selectivity and short duration of action make it a suitable tool for studies of the physiology and pharmacology of \ g=a\ 2\ x=r eq-\ adrenoceptors in man.
Medetomidine (4(5)-[ l-(2,3-dimethylphenyl)ethyl]
imidazole) is a novel imidazole derivative (Karjalainen 1981) . The compound is highly lipophilic (Savola et al. 1986 ) and has high affinity for ct2-adrenoceptors and no or negligible binding to or direct effects on µ-and -opiate, adenosine, D2, histamine, 5-hydroxytryptamine, muscarinic, benzodiazepine, or ß-adrenergic receptors (Virtanen et al. 1988) . Its a^/cxi-binding selectivity ratio has been determined to be 1620 (vs 220 for clonidine; Virtanen et al. 1988 ). In the pithed rat and in isolated organ preparations, medetomidine has displayed selective and potent a,2-receptor agonistic activity, with weak partial ai-agonistic effects at high concentrations (Savola et al. 1986 ).
In rats, medetomidine reduces the release and metabolism of noradrenaline (NA) in the central nervous system (CNS) , and also decreases the turnover of serotonin in several brain areas (Koulu et al. 1987) . Its effects can be antagonized by ci2-adrenoceptor antagonists, but not by prazosin (Scheinin 1986; Savola et al. 1986; Virtanenetal. 1988) .
In this randomized double-blind study, three different doses of medetomidine and saline pla¬ cebo were administered to 8 healthy male volun¬ teers in order to study the acute endocrine effects of the compound. The cardiovascular and seda¬ tive effects of medetomidine observed in this study have been previously published (Scheinin et al. 1987 
